Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: Experimental 23-valent Pneumococcal
- Registration Number
- NCT05731115
- Lead Sponsor
- Sinovac Biotech Co., Ltd
- Brief Summary
This study is a randomized, double-blind phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the consistency of three consecutive lots, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine of commercial scale in participants aged 40-65 years.
- Detailed Description
This study is a randomized, double-blind phase Ⅳ clinical trial in subjects aged 40-65 years to evaluate the lot-to-lot consistency,immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine of commercial scale.The experimental vaccine was manufactured by Sinovac Biotech Co., Ltd.A total of 1800 subjects will be enrolled.The subjects will be randomly divided into three groups in a ratio of 1:1:1 to received one dose of vaccine on day 0.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1800
- Adults aged 40-65 years in stable health;
- The subjects can understand and voluntarily sign the informed consent form;
- Proven legal identity.
- Have received any pneumococcal vaccine;
- History bacterial pneumonia or invasive pneumococcal infectious diseases caused by pneumococci and confirmed by culture;
- Women of childbearing age (menarche to premenopause) are pregnant (including positive urine pregnancy test), breastfeeding or planning pregnancy within 1 month;
- History of asthma, allergy to vaccines or vaccine components, and serious adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema;
- Severe chronic diseases,such as severe cardiovascular diseases, hypertension(Systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg) and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.;
- Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
- Autoimmune disease or immune deficiency/immunosuppression;
- Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;
- Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
- A long history of alcohol or drug abuse;
- Receipt of blood products within in the past 3 months;
- Receipt of other investigational drugs within 30 days prior to receiving the investigational vaccine;
- Receipt of attenuated live vaccines or COVID-19 vaccines in the past 14 days;
- Receipt of inactivated or subunit vaccines in the past 7 days;
- Onset of various acute or chronic diseases within 7 days prior to the study;
- Underarm body temperature before vaccination>37.0°C;
- The subjects participated in other clinical trials during the follow-up period or will be planned to participate other clinical trials within 1 months;
- According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Experimental Vaccine-lot 3 Experimental 23-valent Pneumococcal Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 3. Experimental Vaccine-lot 2 Experimental 23-valent Pneumococcal Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 2. Experimental Vaccine-lot 1 Experimental 23-valent Pneumococcal Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 1.
- Primary Outcome Measures
Name Time Method Immunogenicity index-Geometric Mean Concentration (GMC) 30 days after vaccination GMC for serotype-specific pneumococcal immunoglobulin G (IgG) antibody 30 days after vaccination.
- Secondary Outcome Measures
Name Time Method Immunogenicity index-Geometric Mean Increase (GMI) 30 days after vaccination GMI for serotype-specific pneumococcal IgG antibody 30 days after vaccination.
Safety index-Incidence of adverse reactions Within 7 days after vaccination Incidence of adverse reactions within 7 days after vaccination
Immunogenicity index-Seroconversion rate (2-fold increase rate) 30 days after vaccination Seroconversion rate (2-fold increase rate) for serotype-specific pneumococcal IgG antibody 30 days after vaccination.
Safety index-Incidence of serious adverse events Within 30 days after vaccination Incidence of serious adverse events within 30 days after vaccination.
Trial Locations
- Locations (2)
The First People's Hospital of Yuanping Medical Group
🇨🇳Yuanping, Shanxi, China
Salt Lake District Center for Disease Control and Prevention
🇨🇳Yuncheng, Shanxi, China